A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

Launched by BOEHRINGER INGELHEIM · Jan 28, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called nerandomilast to see if it can help improve lung function in adults with lung fibrosis related to certain autoimmune diseases, like rheumatoid arthritis or systemic sclerosis. To participate, individuals must be 18 years or older and have not experienced any improvement in their lung function after receiving standard treatment with immunosuppressant medications.

Participants will be randomly assigned to either take nerandomilast or a placebo (a tablet that looks like the medication but contains no active ingredients) twice a day for about six months. Throughout the trial, they will visit the study site several times for lung function tests, chest imaging, and questionnaires about their symptoms and quality of life. It's important to note that participants must be on stable treatment with immunosuppressants for a certain period before joining the study. This trial is not yet recruiting, but it aims to determine if nerandomilast can be an effective treatment for those struggling with lung fibrosis due to their autoimmune conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria :
• • Participant has systemic autoimmune rheumatic diseases associated interstitial lung diseases (SARD-ILD), defined as
• • Diagnosis by a rheumatologist with at least 1 of the following SARDs: Rheumatoid arthritis (RA), systemic sclerosis (SSc) (participants must be anticentromere auto-antibody negative), idiopathic inflammatory myopathy (IIM), Sjögren's disease, or Mixed connective tissue disease (MCTD)
• • Presence of fibrotic interstitial lung disease (ILD) on high-resolution computed tomography (HRCT), defined as presence of reticular abnormality with traction bronchiectasis with or without honeycombing (HC), with disease extent \>10% on HRCT performed within 12 months of Visit 1 or, if historical scan is not available, on baseline HRCT taken prior to Visit 2, as confirmed by central review
• * No lung function improvement and no clinically significant ILD improvement as a treatment response to immunosuppressant (IS) therapy according to both criteria:
• • No improvement in absolute forced vital capacity (FVC) % predicted \>5% within the 15 months prior to Visit 1, as measured by 2 spirometry assessments that must be ≥3 months apart. (Note: Visit 1 spirometry may be used to fulfill the inclusion criterion if there is only 1 spirometry reading in the 15 months prior to Visit 1)
• • No clinically significant improvement in ILD based on clinician's judgement (including symptoms, imaging/HRCT, or other assessments as considered relevant and documented by the Investigator)
• • FVC ≥45% of predicted normal at Visit 1
• • Diffusing capacity of the lungs for carbon monoxide (DLCO) ≥25% of predicted normal corrected for haemoglobin (Hb) within 3 months prior to or at Visit 1
• * Participants must be on stable treatment with any IS agent for ≥6 months (or ≥3 months for participants with IIM-ILD) with the following specifications:
• • If using prednisone, participants must be on stable dose for ≥4 weeks prior to Visit 2
• • If using rituximab, participants must have completed their first cycle \>6 months prior to Visit 2
• • If using nintedanib, participants must be on a stable dose for ≥12 weeks prior to Visit 2
• • In the opinion of the Investigator, no change in background standard of care (SoC) treatment with immunosuppressant (IS), immunomodulator (IM), or nintedanib is planned
• • Further inclusion criteria apply
• Exclusion Criteria :
• • Organising pneumonia as predominant pattern in the HRCT
• • Prebronchodilator forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC) \<0.7 at Visit 1
• • Acute ILD exacerbation within 3 months prior to Visit 1 and/or during the screening period, based on Investigator judgement
• • Active vasculitis, unstable or uncontrolled within 8 weeks prior to Visit 1 or during the screening period
• • Any suicidal behaviour in the past 2 years
• • Any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the past 3 months or at Visit 1, and/or at Visit 2
• • Use of any of the following medications: cyclophosphamide within 6 months of Visit 1, pirfenidone within 8 weeks of Visit 1
• • Further exclusion criteria apply